About us

SyndicateNL, the brand was founded in 2020 and is headquartered in Wageningen University and Research Center in the Europe. The team is focusing on the research, development and production of pharmaceuticals, health products, medical beauty, cosmetics, cancer research and genetically controlled plant products. The company carries out the introduction and breeding of seed sources, and the cultivation, production and processing of natural plants in legal areas around the world. 

At the same time, the team is actively participating in international institutional cooperation and conducting clinical research on medical products .

Nordic ÖU Syndicatenl Cannabidiol Pharmaceutical which is the one of members of SYNDICATENL brand, founded in 2024 and headquartered in Tallinn, the capital of Estonia. As a nordic European company, the team is focusing on the global market commercialization of small molecule biopharmaceutical research and development based on natural ingredients, medical beauty product development, health care product research and development.

Syndicate NL B.V., Han Investment B.V., M&Z Europe B.V. Founder & CTO

Possesses extensive professional experience in the extraction technology and process development of active pharmaceutical ingredients; holds multiple patents in the field of food processing, with rich experience in food carrier technology, drug sustained-release technology, and the development of drug delivery technologies based on natural plant extracts; has facilitated several collaborative projects between leading enterprises in Europe and China, as well as key universities; currently dedicated to project development and technology transfer in the fields of health and sustainable development; has conducted in-depth research in the field of plant-based foods and holds invention patents related to plant-based foods; has published in top journals regarding in-depth environmental cost and economic benefit analyses of various processing technologies.

ÖU Syndicatenl Cannabidiol Pharmaceutical Founder & CEO

Focus on the global market commercialization of small molecule biopharmaceutical research and development based on API from natural plants, medical product and cosmetic plastic surgery product development, health product research and development, and other commercialization of  related products and R&D.